Drug intelligence / Profile preview

ERC-872601

Development stage: Unknown
Lead developer: Shionogi
Administration: Intranasal

Overview

ERC-872601 is an investigational intranasal therapeutic candidate being developed by Shionogi for the prevention of influenza. It is currently undergoing early-stage clinical evaluation in Japan. In a randomized, observer-blind, placebo-controlled Phase 1 study (jRCT2031260462), the safety, tolerability, and immunogenicity of intranasal ERC-872601 are being evaluated in healthy adult and elderly participants to support its development for seasonal influenza prophylaxis.

Beyond the preview

Go deeper on ERC-872601.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ERC-872601.

Explore the full profile